Caspase-1 activation during <i>Eh-</i>macrophage contact degrades cullin-1/5. by Attinder Chadha (11414273)

Subjects:

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

SIVcol Nef relocalizes SERINC5 to the proteasome by an Y86 dependent mechanism. by Dorota Kmiec (5646374)

Residuals of the seven evaluated fitting equations. by Kai Roecker (847195)

Subjects:

Mean ± SD values for the parameters found when Eq. 8 (S1 Appendix) was used to model the relationship between time duration of movement (<i>t</i>_<i>dur</i>) and the weig... by Kai Roecker (847195)

Subjects:

Graphical description of the fitting parameters. by Kai Roecker (847195)

Subjects:

<i>HSpeed</i> results overview. by Kai Roecker (847195)

Subjects:

Groups of power-profile curve fittings. by Kai Roecker (847195)

Subjects:

Mean ± SD values for the parameters found with fittings of Eq. 8, S1 Appendix) to the relationship between time duration of movement (<i>t</i>_<i>dur</i>) and maximum hor... by Kai Roecker (847195)

Subjects:

Independence of the lower against the upper asymptotes. by Kai Roecker (847195)

Subjects:

Decrease in PP2A activity increases phosphorylation of p38MAPK, pMAPKAPK2 and Hsp27 in CD133+ cells. by Shih-Pei Lin (117914)

Overview regarding the used assays and observation time points. by Fabian Westhauser (5314436)

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Large circles show mean of cells from 5 fields of view from a single animal. (D) Immunoblot showing p53 protein expression is decreased in colon tissue from 5-month old HA-MAD1 mice after 1 week of 6 mg/kg dox feed as compared to control. …”

CD43^-/- septic mice exhibit decreased frequencies of apoptotic CD8⁺ T_EM as compared to WT septic mice. by Katherine T. Fay (2576998)

“…D) There was a significant decrease in apoptosis of CD44^HI CD62L^LO CD8⁺ T_EM in CD43^-/- septic mice compared to WT septic mice (10.3±1.1 vs 17.9±1.9, p = 0.006). …”

VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”

The shortened version of the Edinburgh Handedness Inventory encompasses 4 items (e.g. writing) scored on a 5-point scale ranging from:” Always right; usually right; both equally; u... by Marcel F. Hinss (14675457)

Possible Points of Canonical Wnt Inhibition. by Laura Corbett (826084)

“…<p>This study has highlighted six possible points of canonical Wnt inhibition occurring in HSCs. (1) Predominantly non-canonical ligand expression. …”

Western blots and semiquantitative analysis of Claudin-5, VEGF-A, PIK3R2, P-Akt/Akt in cerebral ischemic penumbra between groups. by Guangxiao Ni (19713106)

Subjects:

Decreased IL-17A production by DGKζ deficient <i>i</i>NKT cells following α-GalCer stimulation in vitro. by Jinhong Wu (424170)

OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

“…After 4 weeks, when the tumor size was approximately 100 mm³ (T₀) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”